AstraZeneca Plc (LON:AZN) today announced the agreed sale of US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus..
AstraZeneca Plc (LON:AZN) announced today positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at..
AstraZeneca PLC (LON:AZN), today announced Q3 2018 results. Product Sales increased by 4% in the year to date (2% at CER1), supporting full-year guidance. For the quarter, Product Sales increased..
AstraZeneca Plc (LONAZN) has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma,..
AstraZeneca Plc (LON:AZN) announced the agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo..
AstraZeneca Plc (LON:AZN), and its global biologics research and development arm MedImmune, announced today a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating..
AstraZeneca Plc (LON:AZN) and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced today detailed results from the Phase III SOLO-1 trial..
AstraZeneca Plc (LON:AZN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for..
AstraZeneca Plc (LON:AZN) and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by..
AstraZeneca Plc (LON:AZN) completed an agreement with Cheplapharm Arzneimittel GmbH (Cheplapharm) for the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in..
AstraZeneca Plc (LON:AZN) announced today positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT2 inhibitor CVOT conducted to date. The..
AstraZeneca Plc (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment..
AstraZeneca Plc (LON:AZN) and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma,..
AstraZeneca PLC (LON:AZN) announced the following Board and Board Committee appointments. New Non-Executive Director With effect from 1 October 2018, Joseph G. Peter (Joe) is appointed as a Non-Executive Director..
AstraZeneca plc (LON:AZN) and MedImmune, its global biologics research and development arm, today announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe..
AstraZeneca Plc (LON:AZN) today announced that the European Commission has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorisation..
AstraZeneca Plc (LON:AZN) today announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD)...
AstraZeneca Plc (LON:AZN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth..
AstraZeneca PLC (LON:AZN) and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency has granted orphan designation..
AstraZeneca PLC (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has..
